ORI exerted an antileukemia effect in human T‐cell ALL cell line CEM by halting the stimulation of mTOR/P70S6/4EBP1, RAF/ERK, and STAT5 signaling pathways, downregulation of BCL‐2 expression, and upregulation of BAX expression (Yong et al., 2014). Here, BCL2 is linked to acute lymphoblastic leukemia.